Physician profile
Laura Teplitz
NPI 1881814481
$4,447.18
in general payments reported to CMS, 2019-2025
27 companies · $849 in 2025
The $849 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $909 · 2023: $1,497 · 2024: $775 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $963.59 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Xeris Pharmaceuticals, INC. | $741.04 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $561.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $502.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $333.78 | 2021-2022 | |
| Abbott Laboratories | $213.20 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $191.73 | 2021-2025 | Minimed 780g |
| Amgen INC. | $136.39 | 2021-2024 | Evenity, Prolia, Repatha |
| Amneal Pharmaceuticals LLC | $114.21 | 2022-2025 | Unithroid |
| Radius Health, INC. | $97.21 | 2021-2025 | Tymlos |
| Abbvie INC. | $79.34 | 2023-2024 | |
| Mannkind Corporation | $71.68 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $54.07 | 2023-2024 | |
| Corcept Therapeutics | $48.83 | 2024 | Korlym |
| Dexcom, INC. | $43.09 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $43.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.50 | 2024 | Tradjenta, Jardiance |
| Kowa Pharmaceuticals America, INC. | $34.61 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.43 | 2022 | |
| Amryt Pharma Holdings LTD | $23.51 | 2022 | |
| Amarin Pharma, INC. | $22.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.62 | 2022 | |
| Ibsa Pharma INC. | $19.25 | 2021 | |
| Esperion Therapeutics, INC. | $19.21 | 2023 | Nexletol |
| Ipsen Biopharmaceuticals, INC | $18.10 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.16 | 2021 | |
| Clarus Therapeutics INC. | $14.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Teplitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.